Clinical Trial Update: Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluating radiation therapy and temozolomide with either cilengitide or cetuximab for newly diagnosed MGMT-promoter unmethylated glioblastom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• ERBITUX (cetuximab)
• Temodar (Temozolomide)
• cilengitide (cilengitide)

Snippet

Sponsor: Bart Neyns | Conditions: Glioblastoma | Phase 2 | Status: TERMINATED